APO RESEARCH · REPORT
Colloids (Blood Plasma)
Colloids (blood plasma) are the substances of expanding the circulating blood volume, which mainly contain albumin type, gelatin type, dextran type and hydroxyethyl starch type.
Product & engineering
Understand the product.
Colloids (blood plasma) are the substances of expanding the circulating blood volume, which mainly contain albumin type, gelatin type, dextran type and hydroxyethyl starch type.
Colloids (Blood Plasma) can be applied for extensive burns, massive blood or plasma loss and hypovolemic shock. In this report, we calculate colloids (blood plasma) preparations, which is produced by albumin, gelatin, dextran and hydroxyethyl starch.
Selected research
Industry Research
Colloids (Blood Plasma) Industry Research Report 2026
Market perspective
Colloids (blood plasma) are the substances of expanding the circulating blood volume, which mainly contain albumin type, gelatin type, dextran type and hydroxyethyl starch type.
Colloids (Blood Plasma) can be applied for extensive burns, massive blood or plasma loss and hypovolemic shock. In this report, we calculate colloids (blood plasma) preparations, which is produced by albumin, gelatin, dextran and hydroxyethyl starch.
North America is the largest Colloids (Blood Plasma) market with about 33% market share. Europe is follower, accounting for about 28% market share.
Read the full market overview
The key players are CSL Behring, Baxter, Grifols, Octapharma, Kedrion, Shanghai Raas, CTBB, Hualan Bio, Rongsheng Pharmaceutical, Boya Rongsheng, B. Braun Medical, Fresenius Kabi, HOSPIRA, Axa parenterals, Fresenius Kabi(China), CR Double-Crane, Kelun Group, Shandong Qidu Pharmaceutical, Shandong Hualu Pharmaceutical, Minsheng Pharma, Kanglepharm etc. Top 3 companies occupied about 46% market share.
Report Scope
This report quantifies the global Colloids (Blood Plasma) market in terms of revenue (US$ million) and, where applicable, sales volume (MT), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/MT) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Colloids (Blood Plasma) Market by Company
CSL Behring
Baxter
Grifols
Octapharma
Kedrion
Shanghai Raas
CTBB
Hualan Bio
Rongsheng Pharmaceutical
Boya Rongsheng
B. Braun Medical
Fresenius Kabi
HOSPIRA
Axa parenterals
Fresenius Kabi (China)
CR Double-Crane
Kelun Group
Shandong Qidu Pharmaceutical
Shandong Hualu Pharmaceutical
Minsheng Pharma
Kanglepharm
Colloids (Blood Plasma) Segment by Type
Natural Type Colloids (Blood Plasma)
Synthetic Type Colloids (Blood Plasma)
Colloids (Blood Plasma) Segment by Application
Extensive Burns
Massive Blood or Plasma Loss
Hypovolemic Shock
Others
Colloids (Blood Plasma) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Colloids (Blood Plasma) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Colloids (Blood Plasma) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Colloids (Blood Plasma).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Colloids (Blood Plasma) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Colloids (Blood Plasma) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Colloids (Blood Plasma) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Natural Type Colloids (Blood Plasma)
- Synthetic Type Colloids (Blood Plasma)
Applications
- Extensive Burns
- Massive Blood or Plasma Loss
- Hypovolemic Shock
- Others
Companies covered
- CSL Behring
- Baxter
- Grifols
- Octapharma
- Kedrion
- Shanghai Raas
- CTBB
- Hualan Bio
- Rongsheng Pharmaceutical
- Boya Rongsheng
- B. Braun Medical
- Fresenius Kabi
- HOSPIRA
- Axa parenterals
- Fresenius Kabi (China)
- CR Double-Crane
- Kelun Group
- Shandong Qidu Pharmaceutical
- Shandong Hualu Pharmaceutical
- Minsheng Pharma
- Kanglepharm
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Colloids (Blood Plasma) Market Size (2021-2032)
- 2.2.2 Global Colloids (Blood Plasma) Sales (2021-2032)
- 2.2.3 Global Colloids (Blood Plasma) Market Average Price (2021-2032)
- 2.3 Colloids (Blood Plasma) by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Natural Type Colloids (Blood Plasma)
- 2.3.3 Synthetic Type Colloids (Blood Plasma)
- 2.4 Colloids (Blood Plasma) by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Extensive Burns
- 2.4.3 Massive Blood or Plasma Loss
- 2.4.4 Hypovolemic Shock
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Colloids (Blood Plasma) Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Colloids (Blood Plasma) Sales (MT) of Manufacturers (2021-2026)
- 3.3 Global Colloids (Blood Plasma) Revenue of Manufacturers (2021-2026)
- 3.4 Global Colloids (Blood Plasma) Average Price by Manufacturers (2021-2026)
- 3.5 Global Colloids (Blood Plasma) Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Colloids (Blood Plasma), Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Colloids (Blood Plasma), Product Type & Application
- 3.8 Global Manufacturers of Colloids (Blood Plasma), Established Date
- 3.9 Global Colloids (Blood Plasma) Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 CSL Behring
- 4.1.1 CSL Behring Company Information
- 4.1.2 CSL Behring Business Overview
- 4.1.3 CSL Behring Colloids (Blood Plasma) Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 CSL Behring Colloids (Blood Plasma) Product Portfolio
- 4.1.5 CSL Behring Recent Developments
- 4.2 Baxter
- 4.2.1 Baxter Company Information
- 4.2.2 Baxter Business Overview
- 4.2.3 Baxter Colloids (Blood Plasma) Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Baxter Colloids (Blood Plasma) Product Portfolio
- 4.2.5 Baxter Recent Developments
- 4.3 Grifols
- 4.3.1 Grifols Company Information
- 4.3.2 Grifols Business Overview
- 4.3.3 Grifols Colloids (Blood Plasma) Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Grifols Colloids (Blood Plasma) Product Portfolio
- 4.3.5 Grifols Recent Developments
- 4.4 Octapharma
- 4.4.1 Octapharma Company Information
- 4.4.2 Octapharma Business Overview
- 4.4.3 Octapharma Colloids (Blood Plasma) Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Octapharma Colloids (Blood Plasma) Product Portfolio
- 4.4.5 Octapharma Recent Developments
- 4.5 Kedrion
- 4.5.1 Kedrion Company Information
- 4.5.2 Kedrion Business Overview
- 4.5.3 Kedrion Colloids (Blood Plasma) Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Kedrion Colloids (Blood Plasma) Product Portfolio
- 4.5.5 Kedrion Recent Developments
- 4.6 Shanghai Raas
- 4.6.1 Shanghai Raas Company Information
- 4.6.2 Shanghai Raas Business Overview
- 4.6.3 Shanghai Raas Colloids (Blood Plasma) Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Shanghai Raas Colloids (Blood Plasma) Product Portfolio
- 4.6.5 Shanghai Raas Recent Developments
- 4.7 CTBB
- 4.7.1 CTBB Company Information
- 4.7.2 CTBB Business Overview
- 4.7.3 CTBB Colloids (Blood Plasma) Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 CTBB Colloids (Blood Plasma) Product Portfolio
- 4.7.5 CTBB Recent Developments
- 4.8 Hualan Bio
- 4.8.1 Hualan Bio Company Information
- 4.8.2 Hualan Bio Business Overview
- 4.8.3 Hualan Bio Colloids (Blood Plasma) Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Hualan Bio Colloids (Blood Plasma) Product Portfolio
- 4.8.5 Hualan Bio Recent Developments
- 4.9 Rongsheng Pharmaceutical
- 4.9.1 Rongsheng Pharmaceutical Company Information
- 4.9.2 Rongsheng Pharmaceutical Business Overview
- 4.9.3 Rongsheng Pharmaceutical Colloids (Blood Plasma) Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Rongsheng Pharmaceutical Colloids (Blood Plasma) Product Portfolio
- 4.9.5 Rongsheng Pharmaceutical Recent Developments
- 4.10 Boya Rongsheng
- 4.10.1 Boya Rongsheng Company Information
- 4.10.2 Boya Rongsheng Business Overview
- 4.10.3 Boya Rongsheng Colloids (Blood Plasma) Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Boya Rongsheng Colloids (Blood Plasma) Product Portfolio
- 4.10.5 Boya Rongsheng Recent Developments
- 4.11 B. Braun Medical
- 4.11.1 B. Braun Medical Company Information
- 4.11.2 B. Braun Medical Business Overview
- 4.11.3 B. Braun Medical Colloids (Blood Plasma) Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 B. Braun Medical Colloids (Blood Plasma) Product Portfolio
- 4.11.5 B. Braun Medical Recent Developments
- 4.12 Fresenius Kabi
- 4.12.1 Fresenius Kabi Company Information
- 4.12.2 Fresenius Kabi Business Overview
- 4.12.3 Fresenius Kabi Colloids (Blood Plasma) Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Fresenius Kabi Colloids (Blood Plasma) Product Portfolio
- 4.12.5 Fresenius Kabi Recent Developments
- 4.13 HOSPIRA
- 4.13.1 HOSPIRA Company Information
- 4.13.2 HOSPIRA Business Overview
- 4.13.3 HOSPIRA Colloids (Blood Plasma) Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 HOSPIRA Colloids (Blood Plasma) Product Portfolio
- 4.13.5 HOSPIRA Recent Developments
- 4.14 Axa parenterals
- 4.14.1 Axa parenterals Company Information
- 4.14.2 Axa parenterals Business Overview
- 4.14.3 Axa parenterals Colloids (Blood Plasma) Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Axa parenterals Colloids (Blood Plasma) Product Portfolio
- 4.14.5 Axa parenterals Recent Developments
- 4.15 Fresenius Kabi (China)
- 4.15.1 Fresenius Kabi (China) Company Information
- 4.15.2 Fresenius Kabi (China) Business Overview
- 4.15.3 Fresenius Kabi (China) Colloids (Blood Plasma) Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Fresenius Kabi (China) Colloids (Blood Plasma) Product Portfolio
- 4.15.5 Fresenius Kabi (China) Recent Developments
- 4.16 CR Double-Crane
- 4.16.1 CR Double-Crane Company Information
- 4.16.2 CR Double-Crane Business Overview
- 4.16.3 CR Double-Crane Colloids (Blood Plasma) Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 CR Double-Crane Colloids (Blood Plasma) Product Portfolio
- 4.16.5 CR Double-Crane Recent Developments
- 4.17 Kelun Group
- 4.17.1 Kelun Group Company Information
- 4.17.2 Kelun Group Business Overview
- 4.17.3 Kelun Group Colloids (Blood Plasma) Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Kelun Group Colloids (Blood Plasma) Product Portfolio
- 4.17.5 Kelun Group Recent Developments
- 4.18 Shandong Qidu Pharmaceutical
- 4.18.1 Shandong Qidu Pharmaceutical Company Information
- 4.18.2 Shandong Qidu Pharmaceutical Business Overview
- 4.18.3 Shandong Qidu Pharmaceutical Colloids (Blood Plasma) Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 Shandong Qidu Pharmaceutical Colloids (Blood Plasma) Product Portfolio
- 4.18.5 Shandong Qidu Pharmaceutical Recent Developments
- 4.19 Shandong Hualu Pharmaceutical
- 4.19.1 Shandong Hualu Pharmaceutical Company Information
- 4.19.2 Shandong Hualu Pharmaceutical Business Overview
- 4.19.3 Shandong Hualu Pharmaceutical Colloids (Blood Plasma) Sales, Revenue and Gross Margin (2021-2026)
- 4.19.4 Shandong Hualu Pharmaceutical Colloids (Blood Plasma) Product Portfolio
- 4.19.5 Shandong Hualu Pharmaceutical Recent Developments
- 4.20 Minsheng Pharma
- 4.20.1 Minsheng Pharma Company Information
- 4.20.2 Minsheng Pharma Business Overview
- 4.20.3 Minsheng Pharma Colloids (Blood Plasma) Sales, Revenue and Gross Margin (2021-2026)
- 4.20.4 Minsheng Pharma Colloids (Blood Plasma) Product Portfolio
- 4.20.5 Minsheng Pharma Recent Developments
- 4.21 Kanglepharm
- 4.21.1 Kanglepharm Company Information
- 4.21.2 Kanglepharm Business Overview
- 4.21.3 Kanglepharm Colloids (Blood Plasma) Sales, Revenue and Gross Margin (2021-2026)
- 4.21.4 Kanglepharm Colloids (Blood Plasma) Product Portfolio
- 4.21.5 Kanglepharm Recent Developments
5 Global Colloids (Blood Plasma) Market Scenario by Region
- 5.1 Global Colloids (Blood Plasma) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Colloids (Blood Plasma) Sales by Region: 2021-2032
- 5.2.1 Global Colloids (Blood Plasma) Sales by Region: 2021-2026
- 5.2.2 Global Colloids (Blood Plasma) Sales by Region: 2027-2032
- 5.3 Global Colloids (Blood Plasma) Revenue by Region: 2021-2032
- 5.3.1 Global Colloids (Blood Plasma) Revenue by Region: 2021-2026
- 5.3.2 Global Colloids (Blood Plasma) Revenue by Region: 2027-2032
- 5.4 North America Colloids (Blood Plasma) Market Facts & Figures by Country
- 5.4.1 North America Colloids (Blood Plasma) Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Colloids (Blood Plasma) Sales by Country (2021-2032)
- 5.4.3 North America Colloids (Blood Plasma) Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Colloids (Blood Plasma) Market Facts & Figures by Country
- 5.5.1 Europe Colloids (Blood Plasma) Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Colloids (Blood Plasma) Sales by Country (2021-2032)
- 5.5.3 Europe Colloids (Blood Plasma) Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Colloids (Blood Plasma) Market Facts & Figures by Country
- 5.6.1 Asia Pacific Colloids (Blood Plasma) Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Colloids (Blood Plasma) Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Colloids (Blood Plasma) Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Colloids (Blood Plasma) Market Facts & Figures by Country
- 5.7.1 South America Colloids (Blood Plasma) Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Colloids (Blood Plasma) Sales by Country (2021-2032)
- 5.7.3 South America Colloids (Blood Plasma) Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Colloids (Blood Plasma) Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Colloids (Blood Plasma) Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Colloids (Blood Plasma) Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Colloids (Blood Plasma) Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Colloids (Blood Plasma) Sales by Type (2021-2032)
- 6.1.1 Global Colloids (Blood Plasma) Sales by Type (2021-2032) & (MT)
- 6.1.2 Global Colloids (Blood Plasma) Sales Market Share by Type (2021-2032)
- 6.2 Global Colloids (Blood Plasma) Revenue by Type (2021-2032)
- 6.2.1 Global Colloids (Blood Plasma) Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Colloids (Blood Plasma) Revenue Market Share by Type (2021-2032)
- 6.3 Global Colloids (Blood Plasma) Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Colloids (Blood Plasma) Sales by Application (2021-2032)
- 7.1.1 Global Colloids (Blood Plasma) Sales by Application (2021-2032) & (MT)
- 7.1.2 Global Colloids (Blood Plasma) Sales Market Share by Application (2021-2032)
- 7.2 Global Colloids (Blood Plasma) Revenue by Application (2021-2032)
- 7.2.1 Global Colloids (Blood Plasma) Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Colloids (Blood Plasma) Revenue Market Share by Application (2021-2032)
- 7.3 Global Colloids (Blood Plasma) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Colloids (Blood Plasma) Value Chain Analysis
- 8.1.1 Colloids (Blood Plasma) Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Colloids (Blood Plasma) Production Mode & Process
- 8.2 Colloids (Blood Plasma) Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Colloids (Blood Plasma) Distributors
- 8.2.3 Colloids (Blood Plasma) Customers
9 Global Colloids (Blood Plasma) Analyzing Market Dynamics
- 9.1 Colloids (Blood Plasma) Industry Trends
- 9.2 Colloids (Blood Plasma) Industry Drivers
- 9.3 Colloids (Blood Plasma) Industry Opportunities and Challenges
- 9.4 Colloids (Blood Plasma) Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst